Open AccessFeatures of the course of non-alcoholic fatty liver disease in HIV-infected individuals
Author(s) -
В. А. Ахмедов,
Н. Ф. Мамедова,
Андрей Васильевич Вербанов,
О. В. Гаус,
О. В. Гаус
Publication year - 2020
Publication title -
vestnik kluba pankreatologov
Language(s) - English
Resource type - Journals
ISSN - 2077-5067
DOI - 10.33149/vkp.2020.02.07
Subject(s) - lipodystrophy , steatohepatitis , steatosis , fatty liver , medicine , dyslipidemia , metabolic syndrome , population , immunology , gastroenterology , liver disease , hepatitis c , disease , viral load , obesity , human immunodeficiency virus (hiv) , antiretroviral therapy , environmental health
This article reflects the course of non-alcoholic fatty liver disease (NAFLD) in HIV-infected individuals. It is noted that long-term antiretroviral therapy and the use of D-drugs can explain the high prevalence of steatosis in this category of patients. The results of experimental studies that demonstrate the direct effect of HIV on liver steatosis by infection of stellate liver cells, stimulation of abnormal expression of SREBP-1 and PPARγ are considered. The role of HIV-mediated microbial translocation as one of the triggers for the development of non-alcoholic steatohepatitis (NASH), which contributes to chronic inflammation due to an increase in the permeability of the intestinal barrier to bacterial products and endotoxins, is noted. Data are presented confirming the high prevalence of the abnormal distribution of fat and visceral obesity (components of lipodystrophy syndrome) in a cohort of HIV-infected individuals. There was a high prevalence of steatosis and steatohepatitis in HIV-infected patients with lipodystrophy as compared with HIV-infected patients without lipodystrophy. Data showing the high prevalence of NASH in HIV-infected individuals are presented. A high rate of progression of NAFLD in a cohort of HIV-infected individuals was observed, regardless of the presence/absence of a combined viral infection (chronic hepatitis C). It has been established that the classic risk factors for NAFLD (high body mass index, dyslipidemia, metabolic syndrome) can contribute to the rapid progression of the disease in people living with HIV, compared with representatives of the general population.